Overview

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).
Phase:
Early Phase 1
Details
Lead Sponsor:
MediBeacon
Treatments:
Lactulose
Pharmaceutical Solutions